Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
A Phase II, Randomized, Double-blind, Placebo-controlled Dose-ranging Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Pleven, Bulgaria, 5800
-
Plovdiv, Bulgaria, 4002
-
Sofia, Bulgaria, 1233
-
Sofia, Bulgaria, 1431
-
-
-
-
-
St. John's, Canada, A1B 3V6
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 0M3
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 3P4
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
-
-
Ontario
-
Courtice, Ontario, Canada, L1E 3C3
-
Ottawa, Ontario, Canada, K1Y 4E9
-
Windsor, Ontario, Canada, N8X 1K4
-
-
Quebec
-
Laval, Quebec, Canada, H7T 2P5
-
Montreal, Quebec, Canada, H1T 2M4
-
Montreal, Quebec, Canada, H3T 1E2
-
Sainte-foy, Quebec, Canada, G1V 4G2
-
Sherbrooke, Quebec, Canada, J1G 5K2
-
-
-
-
-
Tallinn, Estonia, 10138
-
Tartu, Estonia, 50406
-
Tartu, Estonia, 50708
-
Voru, Estonia, 65609
-
-
-
-
-
Ogre, Latvia, 5001
-
Talsi, Latvia, 3201
-
Tukums, Latvia, 3100
-
Valmiera, Latvia, LV-4201
-
-
-
-
-
Kaunas, Lithuania, 3036
-
Kaunas, Lithuania, 3040
-
Kaunas, Lithuania, 3042
-
Vilnius, Lithuania
-
-
-
-
-
Guadalajara, Mexico, 44280
-
Guadalajara, Mexico, 44349
-
Merida, Mexico, 97000
-
Mexico City, Mexico, 03100
-
Mexico City, Mexico, 06700
-
Mexico City, Mexico, 14050
-
Monterrey, Mexico, 64460
-
Monterrey, Mexico, 64320
-
Monterrey, Mexico, 64410
-
Pachuca, Hidalgo, Mexico, 42039
-
Tijuana, Mexico, 22320
-
-
-
-
-
Panama, Panama
-
-
-
-
-
Ponce, Puerto Rico, 00732-7994
-
-
-
-
-
Arad, Romania, 2900
-
Brasov, Romania, 500326
-
Bucuresti, Romania, 7000
-
Bucuresti, Romania, 020475
-
Galati, Romania, 6200
-
Ploiesti, Romania, 2000
-
Targoviste, Romania, 0200
-
Tirgu-mures, Romania, 4300
-
-
-
-
-
Bracknell, United Kingdom, RG12 1HX
-
Nottingham, United Kingdom, NG2 3HF
-
Plymouth, United Kingdom, PL6 8BX
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
-
-
Arizona
-
Mesa, Arizona, United States, 85206
-
Scottsdale, Arizona, United States, 85251
-
Tucson, Arizona, United States, 85710
-
Tucson, Arizona, United States, 85723
-
-
California
-
Encino, California, United States, 91436
-
Fountain Valley, California, United States, 92708
-
Fremont, California, United States, 94538
-
Fresno, California, United States, 93720
-
Irvine, California, United States, 92618
-
Modesto, California, United States, 95355
-
Pasadena, California, United States, 91106
-
San Bruno, California, United States, 94066
-
Santa Rosa, California, United States, 95405
-
Sunnyvale, California, United States, 94086
-
-
Connecticut
-
Hamden, Connecticut, United States, 06518
-
Norwalk, Connecticut, United States, 06850
-
-
Delaware
-
Newark, Delaware, United States, 19713
-
-
Florida
-
Hollywood, Florida, United States, 33021
-
Jacksonville, Florida, United States, 32204
-
Ocala, Florida, United States, 34471
-
West Palm Beach, Florida, United States, 33401
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
-
Lawrenceville, Georgia, United States, 30045
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
-
-
Indiana
-
Indianapolis, Indiana, United States, 46214-2985
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
-
St. Louis, Missouri, United States, 63104
-
St. Louis, Missouri, United States, 63110
-
-
Montana
-
Billings, Montana, United States, 59101
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-3032
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
-
-
New Jersey
-
Trenton, New Jersey, United States, 08611
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
-
-
New York
-
Buffalo, New York, United States, 14209
-
New Hyde Park, New York, United States, 11040
-
Rochester, New York, United States, 14609
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28209
-
Durham, North Carolina, United States, 27710
-
Greenville, North Carolina, United States, 27858-4354
-
Morrisville, North Carolina, United States, 27560
-
-
Oregon
-
Portland, Oregon, United States, 97201
-
Tualatin, Oregon, United States, 97062
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, United States, 17011
-
Connellsville, Pennsylvania, United States, 15425
-
Philadelphia, Pennsylvania, United States, 19104
-
Philadelphia, Pennsylvania, United States, 19107
-
-
Rhode Island
-
East Providence, Rhode Island, United States, 02914
-
-
South Carolina
-
Greer, South Carolina, United States, 29651
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
-
-
Texas
-
Dallas, Texas, United States, 75230
-
El Paso, Texas, United States, 79902
-
Houston, Texas, United States, 77030
-
Midland, Texas, United States, 79705
-
San Antonio, Texas, United States, 78229
-
San Antonio, Texas, United States, 78229-4801
-
San Antonio, Texas, United States, 78284
-
-
Virginia
-
Lebanon, Virginia, United States, 24266
-
Richmond, Virginia, United States, 23294
-
Virginia Beach, Virginia, United States, 23451
-
-
Washington
-
Edmonds, Washington, United States, 98026
-
Wenatchee, Washington, United States, 98801
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 35 to 75
- Type 2 diabetes for longer than 3 months
- HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening
- FPG (fasting plasma glucose) greater than 126 mg/dL at screening
- BMI (body mass index) less than 40 kg/square meter
Exclusion Criteria:
- Type I diabetes
- Type 2 diabetes patients currently treated with insulin
- Type 2 diabetes patients currently or previously treated with Actos, Avandia or Rezulin
- FPG (fasting plasma glucose) greater than 270 mg/dL at baseline
- Impaired liver or kidney function
- Triglycerides greater than 600 mg/dL
- Uncontrolled hypertension
- Pregnant or lactating women
- Women not using adequate contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WM16177
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.